Skip to content

Leprosy Multidrug Therapy (MDT) Last Mile Supply Chain Survey

Introduction
This short survey is part of the ongoing Leprosy MDT Last-Mile Supply Chain Assessment. Your insights will help identify critical bottlenecks, highlight effective practices, uncover opportunities and offer potential solutions to strengthen the last-mile supply chain for Leprosy MDT. Your contribution is essential to the development of practical, evidence-based solutions and recommendations for Leprosy MDT programs.

All insights shared in this survey will be kept confidential. No material referring to any participant by name, designation, or other information that helps identify them will be collected.

Note: The scope of the survey focuses on insights into MDT for Leprosy.
1.Which country (or region) do you primarily work in?(Required.)
2.What is your primary role?(Required.)
3.What level do you work at?(Required.)
4.How does your program currently track Leprosy MDT stock levels at the health facility level? (Select all that apply)
5.How would you describe the availability of Leprosy MDT blister packs at your level over the past 6 months
6.In your opinion, when Leprosy MDT stock-outs occurred, how long did they typically last?
7.In your opinion, when a stock-out of Leprosy MDT occurs, what is the main cause? (Select all that apply)
8.What is the frequency of Leprosy MDT Resupply at your level?
9.Who usually delivers Leprosy MDT to your level?
10.In your opinion, are storage conditions for Leprosy MDT (temperature, cleanliness, moisture control) adequate at your level?
11.Are Leprosy MDT stock records (e.g., stock cards, registers) maintained and updated regularly?
12.How often do you report Leprosy MDT stock data to the next level?
13.Have you received any training on MDT supply chain management in the past 3 years?
14.In your opinion, what type of support would most improve MDT supply at your level? (Select all that apply)
15.In your opinion, what practices have helped you ensure continuous Leprosy MDT availability?
16.As your program scales up Leprosy prevention, does the supply chain for Single-Dose Rifampicin for Post-Exposure Prophylaxis (SDR-PEP) experience similar bottlenecks to those you face with MDT?
17.Please add any other comments you have on main challenges, opportunities and potential solutions for Leprosy MDT last mile.
Thank you for taking time to share your insights. If you would like further information and to receive updates regarding results of this survey or other results on the Leprosy MDT supply chain assessments click here to register: Sign Up